AU2014244152A1 - Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor - Google Patents

Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor Download PDF

Info

Publication number
AU2014244152A1
AU2014244152A1 AU2014244152A AU2014244152A AU2014244152A1 AU 2014244152 A1 AU2014244152 A1 AU 2014244152A1 AU 2014244152 A AU2014244152 A AU 2014244152A AU 2014244152 A AU2014244152 A AU 2014244152A AU 2014244152 A1 AU2014244152 A1 AU 2014244152A1
Authority
AU
Australia
Prior art keywords
pain
pharmaceutically acceptable
naltrexone
composition
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014244152A
Other languages
English (en)
Inventor
Annette Channa Toledano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allodynic Therapeutics LLC
Original Assignee
Allodynic Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/799,287 external-priority patent/US20130310412A1/en
Priority claimed from US13/837,099 external-priority patent/US9095548B2/en
Priority claimed from US13/841,100 external-priority patent/US9205081B2/en
Priority claimed from US13/851,267 external-priority patent/US20150111916A9/en
Priority claimed from US13/851,773 external-priority patent/US20150111917A9/en
Application filed by Allodynic Therapeutics LLC filed Critical Allodynic Therapeutics LLC
Publication of AU2014244152A1 publication Critical patent/AU2014244152A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014244152A 2013-03-13 2014-03-13 Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor Abandoned AU2014244152A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US13/799,287 2013-03-13
US13/799,287 US20130310412A1 (en) 2010-06-28 2013-03-13 Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
US13/837,099 2013-03-15
US13/841,100 2013-03-15
US13/837,099 US9095548B2 (en) 2010-04-29 2013-03-15 Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain
US13/841,100 US9205081B2 (en) 2010-04-29 2013-03-15 Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
US13/851,267 US20150111916A9 (en) 2010-04-29 2013-03-27 Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
US13/851,773 2013-03-27
US13/851,773 US20150111917A9 (en) 2010-04-29 2013-03-27 Combinations of an Opioid/TLR4 Antagonist and an Alpha-2-Delta Ligand for Use in the Treatment of Pain
US13/851,267 2013-03-27
PCT/US2014/025771 WO2014160077A1 (en) 2013-03-13 2014-03-13 Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor

Publications (1)

Publication Number Publication Date
AU2014244152A1 true AU2014244152A1 (en) 2015-10-01

Family

ID=51625328

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014244152A Abandoned AU2014244152A1 (en) 2013-03-13 2014-03-13 Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor

Country Status (5)

Country Link
EP (1) EP2968293A4 (enExample)
JP (1) JP2016512561A (enExample)
AU (1) AU2014244152A1 (enExample)
CA (1) CA2942641A1 (enExample)
WO (1) WO2014160077A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105449A1 (en) * 2014-12-22 2016-06-30 Seth Lederman Compounds for use as pain therapeutics
CA2996281C (en) * 2015-08-31 2022-03-08 Regents Of The University Of Minnesota Opioid receptor modulators and use thereof
RU2742337C2 (ru) * 2016-09-09 2021-02-04 Такеда Фармасьютикал Компани Лимитед Циклическое соединение
WO2018081792A2 (en) 2016-10-31 2018-05-03 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
WO2025259600A2 (en) * 2024-06-10 2025-12-18 University Of Rochester Brain protein targets for the treatment of migraine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001942T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US20040192715A1 (en) * 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
JP2006131545A (ja) * 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
CA2785056A1 (en) * 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20110269727A1 (en) * 2010-04-29 2011-11-03 Toledano Annette C Composition to reduce allodynic back pain and related method of use
WO2012048294A2 (en) * 2010-10-07 2012-04-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy

Also Published As

Publication number Publication date
WO2014160077A1 (en) 2014-10-02
EP2968293A1 (en) 2016-01-20
CA2942641A1 (en) 2014-10-02
EP2968293A4 (en) 2016-12-28
JP2016512561A (ja) 2016-04-28

Similar Documents

Publication Publication Date Title
Pergolizzi et al. The pharmacological management of dental pain
Mehlisch The efficacy of combination analgesic therapy in relieving dental pain
Menhinick et al. The efficacy of pain control following nonsurgical root canal treatment using ibuprofen or a combination of ibuprofen and acetaminophen in a randomized, double‐blind, placebo‐controlled study
Oertel et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe
AU2022203543A1 (en) Methods of treating inflammation or neuropathic pain
Ryan et al. Gender differences in analgesia for endodontic pain
JP6014702B2 (ja) 線維筋痛症候群の長期治療のためのミルナシプラン
Cordell et al. Comparison of intravenous ketorolac, meperidine, and both (balanced analgesia) for renal colic
AU780013B2 (en) Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
CA2942641A1 (en) Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor
Kaur et al. Antidepressants as antipruritic agents: a review
Ventafridda et al. Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs
CA2926389A1 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
ES2626651T3 (es) Composiciones para el tratamiento de la fatiga crónica
US20130310412A1 (en) Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
MX2007006091A (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante.
TW200412939A (en) Alpha2delta ligands for the treatment of fibromyalgia and other disorders
CN1897956A (zh) 用于治疗肌纤维痛的方法和含有沙利度胺的组合物
Mehlisch et al. Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trial
TW200911225A (en) Methods for improving physical function in fibromyalgia
Cooper et al. The analgesic efficacy of suprofen in periodontal and oral surgical pain
AU2012276476A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
EP4098254A1 (en) Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
Rodríguez-Sánchez et al. Fixed dose combination of magaldrate plus domperidone is more effective than domperidone alone in the treatment of patients with gastroesophageal reflux symptoms: a randomized double-blind study
AU2012203789B2 (en) Milnacipran for the long-term treatment of fibromyalgia syndrome

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted